Drug Database
PI

piroxicam suppositories (Riacen)

✓ Approved

Chiesi Farmaceutici S.p.A. · PTGS1 · 小分子

什么是 piroxicam suppositories?

piroxicam suppositories 是一种小分子,由Chiesi Farmaceutici S.p.A.研发。该药已获批,用于治疗相关适应症,给药途径:Rectal。

药物档案

商品名Riacen
公司Chiesi Farmaceutici S.p.A.
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Rectal
状态Approved

作用机制

分子靶点

piroxicam suppositories 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

piroxicam suppositories 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Hepatobiliary disordersHepatitis✓ Approved

相关研究文献

PubMedTherapeutic advances in musculoskeletal disease2026-11-15

Ultrasound-mediated cavitation of microbubble-infused dressings increases the therapeutic efficacy of piroxicam gel for hand arthritis: An intraindividual randomized controlled trial.

Lai Kuo-Lung KL, Liao Ai-Ho AH, Li Pai-Chi PC

Combining ultrasound (US) with microbubbles (MBs) increases epidermal permeability and thus facilitates the transfer of drugs into deeper tissues. To investigate the efficacy of combining US-mediated MB cavitation with piroxicam gel for hand arthritis. A single-center, open-label, intraindividual randomized controlled trial. Fifty-two adult patients (mean age 55.0 years; 76.9% females) with hand arthritis in at least three symptomatic joints participated in this study. Three affected joints in each patient were randomly assigned to one of three groups: MB/US group, US group, and control group. The MB/US group received US (1 MHz at 0.49 W/cm2 for 3 minutes) along with an MB-infused dressing immediately followed by piroxicam gel application (1%, 0.5-1 g) on days 1, 3, and 5; the US group received US along with pure gel application immediately followed by piroxicam gel application; and the control group received only piroxicam gel application. Assessments were performed before and after treatment using the pain visual analogue scale (VAS) score, the synovial hypertrophy (SH) area on B-mode images, and synovial vascularity in conventional and ultrafast power Doppler (PD) imaging. The therapeutic response was determined by the pain VAS score, B-mode imaging, and PD imaging. The pain VAS score was significantly lower in the MB/US and US groups than in the control group. The SH area improved in 78.8%, 59.6%, and 53.8% of cases in the MB/US, US, and control groups, respectively, while the synovial vascularity improved in 61.5%, 50.0%, and 51.9%, and the therapeutic response rates were 75.0%, 61.5%, and 53.8%, with MB/US showing a significant improvement over control (p = 0.024). US-mediated cavitation of an MB-infused dressing enhances drug delivery and may improve the therapeutic response for hand arthritis, with no adverse events.

PMID 43034546
阅读全文 →
PubMedBulletin of experimental biology and medicine2026-11-15

Effect of Melatonin in Rectal Suppositories on Neurological Status and Blood S100B Protein Levels in Experimental Acute Brain Ischemia.

Osikov M V MV, Shelomentsev A V AV, Shishkova Yu S YS, Boyko M S MS et al.

We studied the effect of melatonin (MT) on the neurological status and serum S100B protein levels in Wistar rats under conditions of experimental acute cerebral ischemia. The animals received daily administrations for 7 days of either a novel 100 mg rectal suppository containing 2.5 mg of MT or a citicoline solution (100 mg/kg, intraperitoneally). On days 3 and 7, neurological status was assessed using the Garcia scale and the limb placing test; serum S100B levels were measured by ELISA. The use of MT-containing suppositories led to a partial recovery of the neurological deficit, improved the limb placing test and Garcia scores, and reduced the serum S100B protein levels. The efficacy of MT in the form of rectal suppositories in correcting neurological deficits was significantly superior to that of the citicoline solution, which may be attributed to optimal pharmacokinetics and pleiotropic mechanisms of action, including direct and indirect antioxidant effects, suppression of neuroinflammation, and modulation of synaptic plasticity. At the same time, citicoline was more efficient in reducing serum S100B protein levels, which is consistent with its primary mechanism of action aimed at repairing cell membranes through enhanced phosphatidylcholine synthesis, leading to stabilization of astrocyte membranes and structural components of the blood-brain barrier.

PMID 43033387
阅读全文 →
PubMedMolecules (Basel, Switzerland)2026-11-14

Optimization of the Technology of Suppositories with CO2 Extract of Rosmarinus officinalis L. and In Vitro Evaluation of Chamazulene Release.

Medeshova Aigul A, Orazbayeva Perizat P, Essedova Aizhan A, Amantayeva Meruyert M et al.

This study investigated manufacturing conditions for suppositories containing a CO2 extract of Rosmarinus officinalis L. herb, using a previously developed formulation, and evaluated a gas chromatography procedure with flame ionization detection (GC-FID) for quantitative marker determination. The effects of key manufacturing parameters were evaluated, and the optimal conditions for base preparation were determined as 70 °C and 120 rpm for 12 min; increasing the agitation speed to 150 rpm did not reduce the processing time. Extract concentrate preparation at 37 °C and 60 rpm required 25 min to achieve visually assessed homogeneity. At 60 rpm, prior concentrate preparation reduced the subsequent mixing time of the suppository mass from 100 to 20 min at each investigated temperature (37, 45, and 60 °C), excluding the time required to prepare the concentrate. Cooling at 8 °C for 60 min was selected on the basis of mechanical-strength measurements. Agar diffusion experiments provided a comparative assessment of the diffusion of colored extract constituents rather than a quantitative measure of chamazulene release or bioavailability. The findings identify candidate manufacturing conditions for further evaluation. Confirmation of marker identity, analytical validity, quantitative content uniformity, and long-term stability is required before reliable product standardization can be established.

PMID 43029312
阅读全文 →
PubMedThe journal of vascular access2026-11-11

Comparative short-term effects of topical piroxicam gel, diclofenac gel, and EMLA cream on pain reduction during intravenous cannulation: A randomized clinical trial.

Amini Nazanin N, Mohammadi Elham E, Babaei Parvin P, Modir Hesameddin H et al.

Intravenous (IV) cannulation is a common invasive procedure associated with pain and discomfort. This study compared the short-term effects of topical Piroxicam gel, Diclofenac gel, and EMLA cream on pain during IV cannulation. This participant- and outcome assessor-blinded randomized clinical trial included 123 hospitalized patients randomly allocated to three equal groups receiving topical Diclofenac gel, Piroxicam gel, or EMLA cream (n = 41/group). Pain intensity was assessed using the Visual Analogue Scale immediately after cannulation and at 5, 10, 15, 30, and 45 min. Data were analyzed using linear mixed-effects models, with Kruskal-Wallis/Dunn and Friedman tests performed as sensitivity analyses. Categorical variables were analyzed using Chi-square or Fisher's exact tests. Baseline characteristics were comparable among groups (all p > .05). The linear mixed-effects model showed significant effects of treatment group (p = .002), time (p < .001), and treatment-by-time interaction (p < .001). Bonferroni-adjusted pairwise comparisons showed lower pain intensity in the Diclofenac and EMLA groups than in the Piroxicam group immediately after cannulation and at 5 min; no significant pairwise differences were observed from 10 to 45 min. Sensitivity analyses supported the overall temporal decline in pain but showed some differences in individual pairwise comparisons. No serious adverse events were reported. Pain intensity declined substantially over time in all groups. In the primary analysis, Diclofenac and EMLA were associated with lower early pain intensity than Piroxicam, although some pairwise findings were sensitive to the analytical approach. Because no placebo control was included, findings should be interpreted as relative rather than absolute treatment effects. The trial was prospectively registered with the Iranian Registry of Clinical Trials (IRCT) under registration number IRCT20180107038251N8 on June 12, 2023 (1402/03/22), prior to the initiation of participant recruitment in October 2025. Available at: https://www.irct.ir/search/result?query=IRCT20180107038251N8.

PMID 43012328
阅读全文 →
PubMedSkeletal radiology2026-11-09

Glycerin suppositories as inexpensive multi-sequence MRI skin markers.

Blum Alain A, Clara Maxime M, Taihi Amina A, Noureddine Raja R et al.

To assess MRI conspicuity and clinical usability of a commercially available glycerin suppository as a low-cost skin marker for musculoskeletal MRI across routine sequences. A glycerin suppository was compared in vivo with vitamin E, water, olive oil, and diluted gadoteric acid solution across routine musculoskeletal MRI sequences. Conspicuity was scored independently by two musculoskeletal radiologists on a 4-point ordinal scale. Clinical usability was retrospectively assessed in 130 examinations at 1.5 and 3 T. One fat-sensitive image set (conventional T1-weighted or Dixon fat-only) and one fluid-sensitive set were scored independently by two readers. Scores of 2 or higher defined usability. Inter-reader agreement was assessed with Cohen kappa. Experimentally, the glycerin suppository showed the most consistent multi-sequence visibility among the tested markers. Unlike vitamin E markers, it remained highly conspicuous on fat-suppressed T1-weighted, fat-suppressed T2-weighted, and Dixon water-only images; it remained visible on STIR but showed lower conspicuity on Dixon fat-only images. Packaging did not affect visibility. Clinically, the marker was usable on both image sets in 123/130 examinations (94.6%) for reader 1 and 120/130 (92.3%) for reader 2. Usability on conventional T1-weighted images was 100% for both readers but decreased on Dixon fat-only reconstructions to 80.0% and 66.7%, respectively. Weighted kappa was 0.90 for fat-sensitive and 0.88 for fluid-sensitive scores. No marker-related image-quality degradation occurred. Glycerin suppositories are inexpensive, disposable MRI skin markers with broad sequence visibility. Their limitation is reduced conspicuity on Dixon fat-only reconstructions.

PMID 43002240
阅读全文 →
PubMedAmerican journal of obstetrics and gynecology2026-11-05

Baclofen Vaginal Suppositories in Chronic Pelvic Pain: a Randomized, Double-Blind, Placebo Controlled Trial.

Rothenberger Rodger W RW, Abraham Alyce A, Gaskins Jeremy T JT, Carbone Laurel L et al.

Pelvic floor muscle dysfunction is a common contributor to chronic pelvic pain (CPP), yet targeted treatment options remain limited. To determine whether baclofen vaginal suppositories in CPP is safe and effective when compared with placebo. This randomized, double-blind, placebo-controlled trial compared 20mg baclofen vaginal suppositories to placebo suppositories nightly in women with CPP. Women older than18 years without allergy to baclofen or the suppository base were included if they had ≥40/100 mm pain on a visual analogue scale (VAS) with palpation of the obturator internus or levator ani on standardized pelvic exam. Improvement in this standardized pelvic exam 100mm VAS pain score represented the primary outcome. Participants completed Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference, PROMIS global health, PROMIS sexual function at baseline, 4, and 8 weeks, with repeat pelvic examination at 8 weeks. The study was powered to detect the minimum clinically important difference (MCID) of 20mm on a 100mm VAS pain scale on a standardized pelvic floor muscle examination with a total sample size of 34, 17 in each group. Adverse events, pill count, and other treatments for CPP during the study period were collected. Differences between treatment groups were assessed using the Mann-Whitney test, and multiple imputation was used to account for missing data. A total of 39 women were enrolled in the study with 37 randomized.19 patients received baclofen vaginal suppositories and 18 received placebo suppositories. Demographic data was similar between groups, with similar mean age (42.5 ± 12.5 baclofen vs 46.3 ± 12.2 placebo) and body mass index (29.4 ± 6.7 vs 29.8 ± 7.6). There was a statistically and clinically significant improvement in the primary outcome of change in the 100mm VAS pain score on pelvic floor muscle examination at 8 weeks relative to baseline in the baclofen group as compared to placebo (median improvement of 33.5 mm [IQR: 30 to 46.230.0] baclofen vs 7.2 mm [0.0 to 10.0] placebo, p=<0.001). Further, patient-reported overall 100mm VAS pain was also significantly improved with baclofen when compared to placebo (median improvement 32.0 mm [14.0 to 43.0] baclofen vs 0.0 mm [-6.5 to 11.8] placebo, p=0.001) (Figure 2). Other validated questionnaires demonstrated no significant differences between baclofen and placebo. Medication compliance, assessed using Spearman correlation between the number of missed doses and the survey score at 8 weeks, did not impact the outcomes among those in the baclofen arm. There were no adverse events in the baclofen group. In the placebo group one participant had intermittent headaches and one participant had irritated vaginal skin. In this appropriately powered, randomized trial, patients experienced statistically and clinically significantly less pain with 8 weeks of nightly baclofen vaginal suppositories when compared to placebo. Baclofen suppositories were shown to be well tolerated with no adverse events.

PMID 42988098
阅读全文 →

注册免费账户还可查看另外 6543 篇文献

免费注册查看全部文献 →

了解更多piroxicam suppositories